{'52WeekChange': 0.040462494,
 'SandP52WeekChange': 0.0644362,
 'address1': "11-12 Street, James's Square",
 'address2': 'Suite 1 3rd Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.25,
 'askSize': 1100,
 'averageDailyVolume10Day': 94287,
 'averageVolume': 89274,
 'averageVolume10days': 94287,
 'beta': None,
 'beta3Year': None,
 'bid': 8.76,
 'bidSize': 1800,
 'bookValue': -1.893,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.63,
 'dayLow': 9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -2.285,
 'enterpriseToRevenue': None,
 'enterpriseValue': 316469056,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 10.136,
 'fiftyTwoWeekHigh': 15.98,
 'fiftyTwoWeekLow': 6.55,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 5469347,
 'forwardEps': -5.33,
 'forwardPE': -1.6885554,
 'fromCurrency': None,
 'fullTimeEmployees': 70,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.77321,
 'heldPercentInstitutions': 0.25993,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1585612800,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/urovant.com',
 'longBusinessSummary': 'Urovant Sciences Ltd., a clinical-stage '
                        'biopharmaceutical company, focuses on developing and '
                        'commercializing therapies for urologic conditions in '
                        "the United States. The company's lead product "
                        'candidate is vibegron, an oral small molecule beta-3 '
                        'agonist for the treatment of overactive bladder '
                        '(OAB), OAB in men with benign prostatic hyperplasia, '
                        'and abdominal pain due to irritable bowel syndrome. '
                        'It is also developing URO-902, a gene therapy for '
                        'patients with OAB who have failed oral '
                        'pharmacological therapy. The company was formerly '
                        'known as Thalavant Sciences Ltd. and changed its name '
                        'to Urovant Sciences Ltd. in January 2017. Urovant '
                        'Sciences Ltd. was founded in 2016 and is based in '
                        'London, the United Kingdom. Urovant Sciences Ltd. '
                        'operates as a subsidiary of Sumitovant Biopharma Ltd.',
 'longName': 'Urovant Sciences Ltd.',
 'market': 'us_market',
 'marketCap': 277193696,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_573918458',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -146744992,
 'nextFiscalYearEnd': 1648684800,
 'open': 9.63,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 20 7400 3347',
 'previousClose': 9.67,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.63,
 'regularMarketDayLow': 9,
 'regularMarketOpen': 9.63,
 'regularMarketPreviousClose': 9.67,
 'regularMarketPrice': 9.63,
 'regularMarketVolume': 35045,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 30520000,
 'sharesPercentSharesOut': 0.0298,
 'sharesShort': 918890,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 828154,
 'shortName': 'Urovant Sciences Ltd.',
 'shortPercentOfFloat': 0.1157,
 'shortRatio': 6.87,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'UROV',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -4.824,
 'twoHundredDayAverage': 10.533957,
 'volume': 35045,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.urovant.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'SW1Y 4LB'}